EHA 2017

Area: Hematology

Location: Madrid, Spain

Date: June 22 to June 25

Description:

European Hematology Association.


Search in Scientific Content:
Date
Filters:
Can the mu
10:02

Can the mutational landscape of AML inform targeted treatment?

Presenter: Charles Craddock
Hematology
Shifting t
9:32

Shifting treatment paradigms" means in DLBCL

Presenter: Umberto Vitolo
Hematology
Update on
7:34

Update on follicular lymphoma: Time beyond chemotherapy?

Presenter: Kai Hübel
Hematology
Biosimilar
12:25

Biosimilars for Hematologic Malignancies: The Path to Sustainable Care; The role of biosimilars in promoting sustainability of care [presentation and panel discussion]

Presenter: Paul Cornes
Hematology
A look at
8:47

A look at biosimilars development

Presenter: Arnold G. Vulto
Hematology
Molecular
11:40

Molecular Monitoring in the Setting of Deep Molecular Response and TFR

Presenter: Susan Branford
Hematology
Acceptable
6:27

Acceptable therapeutic approach in relapsed/refractory Mantle Cell Lymphoma

Presenter: Martin Heinz Dreyling
Hematology
IBRUTINIB
3:02

IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY

Presenter: Iskra Pusic
Hematology
Data that
2:28

Data that can change the way cancer patients of 65 years and older are treated with anticoagulants, possibly preventing mortality

Presenter: Alejandro Lazo-Langner
Hematology
IBRUTINIB,
4:57

IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)

Presenter: Nitin Jain
Hematology
Prioritizi
8:52

Prioritizing therapies in CLL

Presenter: Clemens Wendtner
Hematology
DEEP AND D
14:16

DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT

Presenter: Shaji Kumar
Hematology
DASATINIB
5:30

DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL

Presenter: Christian Michel Zwaan
Hematology
Patient as
8:52

Patient assessment: Optimising the stratification of patients with CLL / How does our understanding of signaling pathways inform treatment decisions? / Future goals of treatment: Finite duration as a desirable goal

Presenter: Paolo Ghia
Hematology
COMPARING ...
2:49

COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB IN PATIENTS WITH DIPSS LOW/INTERMEDIATE-1–, INTERMEDIATE-2–, AND HIGH-RISK MYELOFIBROSIS IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY

Presenter: Martin Griesshammer
Hematology
Interview
2:27

Interview with Peter Borchmann

Presenter: Peter Borchmann
Hematology

ASH 2018

2018-12-01 - 2018-12-04
San Diego, United States

EHA 2018

2018-06-14 - 2018-06-17
Stockholm, Sweden

ASH 2017

2017-12-09 - 2017-12-12
Atlanta, United States

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASH 2016

2016-12-03 - 2016-12-06
San Diego, United States

ASH 2015

2015-12-05 - 2015-12-08
Orlando, United States

EHA 2015

2015-06-11 - 2015-06-14
Vienna, Australia